Long-term survival after development of acute myocardial infarction has improved after a more widespread use of thrombolysis and aspirin.

• We describe the mortality during the subsequent 5 years after development of acute myocardial infarction prior to and after the introduction of a more widespread use of thrombolytic agents and aspirin in the community of Göteborg. During period I, 4% received thrombolysis as compared with 32% during period II (p < 0.0001). The corresponding figures for prescription of aspirin at discharge were 14 and 84%, respectively (p < 0.0001). The overall 5-year mortality was 48% during period I and 46% during period II (p = 0.09). However, the age-adjusted mortality during period II was significantly reduced (risk ratio 0.86; 95% confidence interval 0.78-0.95; p = 0. 004). There was no significant interaction between improvement in survival and sex or any other parameter reflecting patients' clinical history.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

Aged

Aspirin

therapeutic use

Cardiotonic Agents

therapeutic use

Confidence Intervals

Female

Fibrinolytic Agents

therapeutic use

Humans

Likelihood Functions

Longitudinal Studies

Male

Myocardial Infarction

drug therapy

mortality

Odds Ratio

Patient Discharge

Platelet Aggregation Inhibitors

therapeutic use

Proportional Hazards Models

Sex Factors

Survival Rate

Sweden

epidemiology

Thrombolytic Therapy

Treatment Outcome

Ventricular Fibrillation

epidemiology

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)